Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Eur Rev Med Pharmacol Sci ; 27(20): 9510-9520, 2023 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-37916318

RESUMEN

OBJECTIVE: Hand osteoarthritis (OA) is associated with considerable disability, especially in the elderly patient population. Paraffin wax (PW) and prolotherapy (P) are non-pharmacological treatment methods used in this setting. This study aimed to compare the therapeutic efficacy of P and PW in hand osteoarthritis. PATIENTS AND METHODS: This study was designed as a single-center, randomized-controlled trial conducted at our Physical Medicine and Rehabilitation Clinic between February 2019 and July 2020. Patients with bilateral hand OA were divided into PW and P treatment groups. The PW group was treated 5 days per week for 2 weeks. The P group received an injection of dextrose solution into the ligaments of painful joints once weekly for three weeks. Visual analog scale (VAS), Duruoz Hand Index (DHI) scale, hand dynamometer for grip strength, and pinch meter for lateral pinch were used for baseline and post-treatment follow-up assessments. RESULTS: Overall, 42 patients were included. The VAS scores significantly decreased in both PW and P groups (p=0.024 and p=0.014). Baseline and third-month post-treatment VAS scores did not significantly differ (p=0.581). The DHI scores improved significantly in both groups (p<0.001 and p<0.001), being higher in the P than in the PW group (p=0.042). Right- and left-hand grip strength increased significantly in PW and P groups (p<0.001, p=0.001; p=0.013, p=0.002, respectively). CONCLUSIONS: Both treatment methods were effective regarding pain and grip strength; however, P improved the hand functions more significantly.


Asunto(s)
Osteoartritis , Proloterapia , Humanos , Anciano , Parafina/uso terapéutico , Fuerza de la Mano , Proloterapia/métodos , Osteoartritis/tratamiento farmacológico , Mano , Resultado del Tratamiento
2.
Epilepsy Res ; 25(3): 185-90, 1996 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-8956915

RESUMEN

The present study was undertaken to evaluate the antiseizure activity spectrum of insulin against various behavioral seizure models in rats. Insulin was injected intraperitoneally (i.p.) at a test dose of 1 U/kg. Dextrose (3 g/kg) was administered simultaneously with insulin to counteract its hypoglycemic effect and induce a normoglycemic state. Insulin was found to significantly decrease the incidence, intensity and mortality rate and prolong the latency of generalized tonic-clonic convulsions induced by pentylenetetrazole (60 mg/kg i.p.) and significantly decrease the intensity and mortality rate and prolong the latency of generalized tonic-clonic convulsions induced by penicillin (2000 U/intracerebrocortical). Insulin was not only found to prolong the latency of all the seizure components but was found to reduce the incidence of focal myoclonic twitches and generalized tonic-clonic convulsions induced by kainic acid (12 mg/kg i.p.) as well. Insulin was shown to be ineffective to suppress ouabain (5 micrograms/intracerebroventricular) induced seizures. These findings indicate that insulin possesses a broad spectrum of antiseizure activity in rats. Interaction with brain Na(+)-K(+)-ATPase has been discussed as a possible mechanism of action.


Asunto(s)
Anticonvulsivantes/uso terapéutico , Convulsivantes/antagonistas & inhibidores , Hipoglucemiantes/uso terapéutico , Insulina/uso terapéutico , Convulsiones/tratamiento farmacológico , Animales , Anticonvulsivantes/sangre , Glucemia/metabolismo , Evaluación Preclínica de Medicamentos , Glucosa/farmacología , Hipoglucemiantes/sangre , Insulina/sangre , Ácido Kaínico/antagonistas & inhibidores , Masculino , Ouabaína/antagonistas & inhibidores , Penicilinas/antagonistas & inhibidores , Pentilenotetrazol/antagonistas & inhibidores , Ratas , Ratas Wistar , Tiempo de Reacción/efectos de los fármacos , Convulsiones/inducido químicamente
3.
Neurol Res ; 15(5): 310-5, 1993 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-7905604

RESUMEN

The efficacy of sodium nitroprusside in resolving cerebral vasospasm was evaluated with multicisternal injections. Twelve animals received fresh, unheparinized arterial blood via three injections (15 ml total) into the cisterna magna. Selective vertebral arteriography was performed on Day 0, and blood injections were performed on the second and third days after the first injection. On the seventh day selective arteriography was performed to evaluate the diameter of the basilar artery. In the sodium nitroprusside group, intrathecal injections of the drug were started on Day 4 and continued for two days (25 micrograms/kg/day). The diameter of the basilar artery was reduced 72.98 +/- 11.07% in control experiments. For the animals treated with intrathecal sodium nitroprusside, the mean diameter of the basilar artery was reduced 29.25 +/- 4.54%. The effect of intrathecal sodium nitroprusside on intracranial pressure (ICP), blood pressure (BP) and electrocardiogram (ECG) was also evaluated in 14 animals. There were no prominent changes in ICP, BP, or ECG when sodium nitroprusside was given intrathecally, but BP decreased and ICP and heart rate increased with intravenous doses of sodium nitroprusside. These results support the hypothesis that sodium nitroprusside administered intrathecally is an effective treatment for cerebral vasospasm.


Asunto(s)
Ataque Isquémico Transitorio/tratamiento farmacológico , Nitroprusiato/uso terapéutico , Animales , Arteria Basilar/efectos de los fármacos , Arteria Basilar/patología , Presión Sanguínea/efectos de los fármacos , Angiografía Cerebral , Enfermedad Crónica , Perros , Método Doble Ciego , Evaluación Preclínica de Medicamentos , Electrocardiografía/efectos de los fármacos , Femenino , Inyecciones Intravenosas , Inyecciones Espinales , Presión Intracraneal/efectos de los fármacos , Ataque Isquémico Transitorio/diagnóstico por imagen , Ataque Isquémico Transitorio/etiología , Masculino , Nitroprusiato/administración & dosificación , Nitroprusiato/toxicidad , Distribución Aleatoria , Hemorragia Subaracnoidea/complicaciones , Vasodilatación/efectos de los fármacos
5.
Nephron ; 52(3): 227-30, 1989.
Artículo en Inglés | MEDLINE | ID: mdl-2662047

RESUMEN

In order to evaluate the antihypertensive effectiveness and interaction with ciclosporin A (CS-A) nitrendipine, a dihydropyridine derivative calcium entry blocking agent, was used in 16 (13 men, 3 women) hypertensive renal posttransplant patients followed by the Nephrology Department of Hacettepe University Hospital. The patients did not receive any antihypertensive drug for a 7-day period. They were then given 20 mg/day nitrendipine for 3 weeks. At the end of this period, mean (+/- SE) supine blood pressure fell from 163/108 +/- 3.6/1.87 to 141/87 +/- 3.8/2.2 mm Hg (p less than 0.01), while the heart rate was unchanged. 14 of 16 patients achieved full control of blood pressure levels with 20 mg/day nitrendipine, and only 2 patients needed a higher dosage of 30 mg/day (20 + 10 mg). After 3 weeks of treatment no significant variations in blood chemistry or renal functional parameters were noticed. There was also no difference between blood CS-A levels before and after treatment with nitrendipine (218.06 +/- 33 vs. 222.68 +/- 26 ng/ml, p greater than 0.05). We conclude that short-term therapy with nitrendipine in renal post-transplant patients does not appear to be harmful and longer term studies are needed to fully evaluate safety and efficacy of this drug. Because it influences neither blood chemistry nor renal functional parameters and blood CS-A level, it may be preferable to other calcium channel blocking agents in this group of patients.


Asunto(s)
Hipertensión/tratamiento farmacológico , Trasplante de Riñón , Nitrendipino/uso terapéutico , Adulto , Presión Sanguínea/efectos de los fármacos , Ciclosporinas/sangre , Ciclosporinas/uso terapéutico , Interacciones Farmacológicas , Femenino , Humanos , Hipertensión/sangre , Masculino , Nitrendipino/administración & dosificación , Nitrendipino/farmacología , Estudios Prospectivos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA